Relmada Therapeutics, Inc. (RLMD)
Market Cap | 68.02M |
Revenue (ttm) | n/a |
Net Income (ttm) | -157.04M |
Shares Out | 30.10M |
EPS (ttm) | -5.30 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 339,092 |
Open | 2.25 |
Previous Close | 2.24 |
Day's Range | 2.12 - 2.32 |
52-Week Range | 1.81 - 38.68 |
Beta | 0.16 |
Analysts | Buy |
Price Target | 11.60 (+413.27%) |
Earnings Date | May 4, 2023 |
About RLMD
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for RLMD stock is "Buy." The 12-month stock price forecast is $11.6, which is an increase of 413.27% from the latest price.
News

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
CORAL GABLES, Fla. , March 23, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provide...

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 23, 2023
CORAL GABLES, Fla. , March 17, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announc...

Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors
CORAL GABLES, Fla. , Jan. 12, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announce...

Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer
CORAL GABLES, Fla. , Jan. 9, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced...

Relmada Therapeutics shares decline 40% on Thursday
Shares of Relmada Therapeutics Inc. RLMD, -0.95% tumbled about 40% in premarket trading on Thursday, the day after the company said its experimental depression drug did not meet the primary endpoint i...

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder
Company to Host Conference Call Today, December 7, 2022, at 5:00 PM ET CORAL GABLES, Fla. , Dec. 7, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company a...

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
CORAL GABLES, Fla. , Nov. 10, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided...

Relmada Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 10, 2022
CORAL GABLES, Fla. , Nov. 8, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced...

Steven Cohen's Firm Boosts Stakes in Relmada and Immunic
Steven Cohen (Trades, Portfolio), chairman and CEO of Point72 Asset Management, disclosed in regulatory filings that his firm established a position in Progress Acquistion Corp. ( PGRWU , Financial) a...

Relmada (RLMD) Lead Candidate Fails Late-Stage Depression Study
Relmada's (RLMD) phase III study, evaluating REL-1017 in major depressive disorder, fails to achieve statistical significance. Shares plunge 80% following the news.

Why Is Relmada (RLMD) Stock Down 78% Today?
Source: Shutterstock Relmada Therapeutics (NASDAQ: RLMD) stock is plummeting on Thursday as investors react to results from a Phase 3 clinical trial. Unfortunately for RLMD stock, its RELIANCE III st...

Relmada's stock tumbles 80% after its depressive disorder drug failed a late-stage study
Shares of Relmada Therapeutics Inc. RLMD, -0.97% fell 80.0% in premarket trading on Thursday after the biotech said its experimental treatment for major depressive disorder as a monotherapy did not me...

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder
RELIANCE I and II Adjunctive MDD Trials Continue to Advance CORAL GABLES, Fla. , Oct. 13, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing ...

Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder
CORAL GABLES, Fla. , Sept. 20, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announc...

Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
CORAL GABLES, Fla. , Aug. 11, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD) ("Relmada," the "Company," "we," "us, "our"), a late-stage biotechnology company addressing diseases of the...

Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder
CORAL GABLES, Fla. , Aug. 9, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced...

Relmada Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022
CORAL GABLES, Fla. , Aug. 5, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced...

Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial
Company Continues Commercial Preparations in Advance of Phase III Clinical Trial Readouts for REL-1017 in Major Depressive Disorder Expected in 2022 CORAL GABLES, Fla. , July 21, 2022 /PRNewswire/ -- ...

Relmada Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
CORAL GABLES, Fla. , June 7, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced...

Relmada Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference
CORAL GABLES, Fla. , June 2, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced...

Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2022 Annual Meeting
CORAL GABLES, Fla., May 25, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today ...

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
CORAL GABLES, Fla. , May 5, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a...

Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology
CORAL GABLES, Fla. , April 29, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced tod...

Relmada Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022
CORAL GABLES, Fla. , April 28, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announc...

Relmada Therapeutics to Present Data at the Ketamine & Related Compounds International Hybrid Conference 2022
CORAL GABLES, Fla. , April 4, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced toda...